NCT06059261 2026-02-18
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Chongqing University Cancer Hospital
Phase 2 Recruiting
Clinical Trials
46 trialsNCT07327411 2026-01-08
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT05959356 2025-12-17
CEIL
Sun Yat-sen University
Phase 2 Recruiting
NCT07260305 2025-12-03
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Kangabio AUSTRALIA LTD PTY
Phase 1 Recruiting
NCT07159191 2025-09-08
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT07142863 2025-08-27
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT06772233 2025-07-31
A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
Peking University
Phase 2 Not yet recruiting
NCT07003815 2025-06-04
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Tongji Hospital
Phase 2 Not yet recruiting
NCT03478488 2025-05-29
KN035-BTC
3D Medicines
Phase 3 Active not recruiting
NCT05112991 2025-05-29
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
3D Medicines
Phase 2 Recruiting
NCT05941325 2025-05-18
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Shanghai 6th People's Hospital
Phase 2 Recruiting
NCT06074497 2025-02-07
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.
Kangabio AUSTRALIA LTD PTY
Phase 1 Active not recruiting
NCT06791083 2025-01-24
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
First Affiliated Hospital of Fujian Medical University
Phase 2 Recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT04910386 2024-08-14
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
3D Medicines
Phase 2 Not yet recruiting
NCT05068427 2024-08-07
Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.
Chipscreen Biosciences, Ltd.
Phase 2 Completed
NCT06498622 2024-07-12
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
Anhui Provincial Hospital
Phase 2 Recruiting
NCT04480502 2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2 Active not recruiting
NCT06014372 2024-04-12
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT06321081 2024-03-20
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Beijing Hospital
Phase 2 Recruiting
NCT06301828 2024-03-08
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown
NCT06202014 2024-01-19
Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05237349 2024-01-05
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT06108726 2023-10-31
A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer
Northern Jiangsu People's Hospital
Phase 2 Unknown
NCT06060704 2023-10-11
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05448820 2023-09-21
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Unknown
NCT05969847 2023-08-01
TRACE-LE
Fujian Medical University Union Hospital
Phase 2 Not yet recruiting
NCT05203276 2023-06-22
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
The First People's Hospital of Lianyungang
Phase 2 Unknown
NCT05752136 2023-05-08
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
Sir Run Run Shaw Hospital
Phase 3 Recruiting
NCT05799469 2023-04-05
Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer
Chongqing University Cancer Hospital
Phase 2 Not yet recruiting
NCT05552651 2022-09-23
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Air Force Military Medical University, China
Phase 2 Unknown
NCT05551247 2022-09-22
Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT05529355 2022-09-07
Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer
Anhui Chest Hospital
Phase 2 Unknown
NCT05422183 2022-06-16
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
Phase 2 Unknown
NCT05417230 2022-06-14
RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT05414630 2022-06-10
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
Anhui Provincial Cancer Hospital
Phase 2 Unknown
NCT05385185 2022-05-23
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
Hebei Medical University
Phase 2 Unknown
NCT05360979 2022-05-04
A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC
Second Xiangya Hospital of Central South University
Phase 2 Unknown
NCT05335460 2022-04-19
To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05298020 2022-03-28
Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Unknown
NCT03101488 2022-03-03
Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
3D Medicines
Phase 1 Completed
NCT05243355 2022-02-17
Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC
Qilu Hospital of Shandong University
Phase 2 Unknown
NCT03248843 2022-02-08
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
3D Medicines
Phase 1 Completed
NCT02827968 2021-06-02
Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
3D Medicines
Phase 1 Completed
NCT04182789 2019-12-02
CPOG035-01
RenJi Hospital
Phase 2 Unknown
NCT04034823 2019-07-26
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown